Summary
The AI-generated content provided is not a set of ZONISADE prescribing-info medical claims to verify against the supplied FDA label excerpts; it contains non-label retail/pricing statements and an incomplete/unspecified set of medication-use claims. As a result, label alignment cannot be reliably established.
Category Scores
Accurate Statements
Unsupported Statements
In the US, zonisamide is generally sold as a generic.
No support in the provided ZONISADE prescribing information excerpts (pricing/generic status is not addressed).
Zonisamide prices without insurance vary by pharmacy.
No pricing/market-access information is included in the provided prescribing information excerpts.
Zonisamide prices without insurance vary by dose (capsule strength).
No pricing/dose-strength pricing relationship is included in the provided prescribing information excerpts.
Zonisamide prices without insurance vary depending on whether the drug is available generically.
No pricing/generic availability information is included in the provided prescribing information excerpts.
Exact prices for zonisamide change daily.
No pricing information is included in the provided prescribing information excerpts.
Zonisamide is an antiseizure medicine.
While the label excerpt indicates treatment of partial-onset seizures, the AI statement is general and not explicitly stated in the supplied label text as phrased; cannot be confirmed from provided excerpts.
Zonisamide is used for certain seizure types.
The label specifies adjunctive therapy for partial-onset seizures in adults and pediatric patients 16 years and older, but the AI statement is vague (“certain seizure types”) and does not match the label’s specific indication language.
Zonisamide is sometimes used for other off-label indications.
No off-label use statements are included in the provided prescribing information excerpts.
Switching from zonisamide depends on diagnosis, seizure control history, and side-effect profile.
The provided excerpts do not describe decision criteria for switching; label excerpts only include contraindications and specific warnings/precautions and withdrawal guidance.
Contradictions
Important Omissions
Any explicit, label-grounded indication statement for ZONISADE (adjunctive therapy for partial-onset seizures in adults and pediatric patients 16 years and older) and related dosing/administration details.
Importance:
Moderate
Key safety/monitoring warnings from the provided label excerpts (e.g., metabolic acidosis monitoring with serum bicarbonate, pediatric hyperthermia/oligohidrosis, acute myopia/angle closure glaucoma symptoms and discontinuation, suicidal ideation monitoring, renal function limits, and withdrawal guidance).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The provided statements are largely non-label retail/generic/pricing assertions and generalities; they do not provide specific dosing, contraindications, or direct safety guidance. However, the lack of label-grounded safety/monitoring information represents an audit failure for prescribing-information alignment.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Statements include pricing/generic-market claims not covered by the supplied prescribing information and several vague/unsupported medication-use statements not explicitly supported by the provided label excerpts.
Suggested Improvement
Evaluate only claims that directly quote what the AI stated about ZONISADE prescribing (indication, dosing/administration, contraindications, warnings/precautions, interactions, specific populations, adverse reactions, and monitoring). Remove or segregate non-label pricing/generic-market content; ensure medication-use statements match the label’s specific wording (e.g., partial-onset seizures, adjunctive therapy, and age 16+ for this product).